Corporate Governance

Basic Approach to Corporate Governance

Innovacell develops and commercializes therapeutic products and formulations based on human cells, including regenerative medicine products, Advanced Therapy Medicinal Products (ATMPs), and Human Cells, Tissues, and Cellular and Tissue-based Products (HCT/Ps). Through the global provision of these therapies, we aim to improve patients' health and quality of life (QOL).

In collaboration with our subsidiary, Innovacell GmbH (Austria), we are currently engaged in the research, development, and commercialization of autologous cell therapy products for the treatment of incontinence, specifically targeting urge fecal incontinence, passive fecal incontinence, and stress urinary incontinence.

To achieve sustainable development, long-term growth, and enhanced corporate value, it is essential that we earn and maintain the trust of all stakeholders, including our shareholders. Recognizing the critical importance of a robust organizational structure and effective internal control systems that enable adaptability to a changing business environment, we remain committed to continuously strengthening and enhancing our corporate governance framework.